Pacer Advisors, Inc. Heron Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

$39 Billion
Q2 2024

A detailed history of Pacer Advisors, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 1,465 shares of HRTX stock, worth $2,798. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,465

Holding current value

$2,798

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.32 - $3.86 $3,398 - $5,654	1,465 New	1,465 $5,000
Q2 2021 Jul 21, 2021	SELL	$13.27 - $18.48 $61,095 - $85,081	-4,604 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$14.49 - $20.72 $2,840 - $4,061	-196 Reduced 4.08%	4,604 $75,000
Q4 2020 Jan 20, 2021	BUY	$14.61 - $22.14 $11,600 - $17,579	794 Added 19.82%	4,800 $102,000
Q3 2020 Oct 19, 2020	BUY	$13.67 - $17.77 $54,762 - $71,186	4,006 New	4,006 $59,000
Q4 2018 Feb 13, 2019	SELL	$22.03 - $32.01 $155,377 - $225,766	-7,053 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$30.0 - $40.85 $211,590 - $288,115	7,053 New	7,053 $223,000
Q1 2018 May 14, 2018	SELL	$18.43 - $28.8 $29,488 - $46,080	-1,600 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.8 - $18.85 $23,680 - $30,160	1,600	1,600 $29,000

Others Institutions Holding HRTX

# of Institutions

193

Shares Held

129M

Call Options Held

94.7K

Put Options Held

148K

Rubric Capital Management LP New York, NY

26.7M
Shares

$51 Million
2.77% of portfolio
Vanguard Group Inc Valley Forge, PA

8.62M
Shares

$16.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

8.33M
Shares

$15.9 Million
0.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

7.6M
Shares

$14.5 Million
0.05% of portfolio
Velan Capital Investment Management LP Alpharetta, GA

6.99M
Shares

$13.3 Million
58.47% of portfolio

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $227M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.

Account